Drug Discoveries & Therapeutics
Online ISSN : 1881-784X
Print ISSN : 1881-7831
ISSN-L : 1881-7831
Case Report
Early small bowel perforation due to aflibercept
Toufic MoussallemChetana LimMichael OsseisFrancesco EspositoEylon LahatLiliana FuentesChady SalloumDaniel Azoulay
Author information

2017 Volume 11 Issue 5 Pages 291-292


In patients with malignancy who receive aflibercept based chemotherapy, gastrointestinal perforation is among the reported adverse events with a prevalence of 1.9%. This complication may lead to mortality up to 10.8%. We here report a case of small bowel perforation that occurred fifteen days after the first cycle of aflibercept in a 58-year old female who had metachronous colorectal liver metastases. Emergency laparotomy was performed and revealed a small bowel perforation without any anastomotic dehiscence. Surgery was followed by uneventful outcome. The use of aflibercept in patients with malignancy may be associated with very early gastrointestinal perforation and this should be known by oncologist and surgeons.

Information related to the author
© 2017 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article